Outset Medical, Inc. $OM is BML Capital Management LLC’s 5th Largest Position

BML Capital Management LLC grew its stake in shares of Outset Medical, Inc. (NASDAQ:OM) by 250.2% in the first quarter, Holdings Channel.com reports. The fund owned 1,902,201 shares of the company’s stock after purchasing an additional 1,359,021 shares during the period. Outset Medical makes up about 4.7% of BML Capital Management LLC’s holdings, making the stock its 5th largest holding. BML Capital Management LLC owned 0.10% of Outset Medical worth $7,304,000 at the end of the most recent reporting period.

Several other institutional investors have also modified their holdings of the company. Millennium Management LLC grew its holdings in shares of Outset Medical by 165.8% in the 3rd quarter. Millennium Management LLC now owns 421,409 shares of the company’s stock worth $5,950,000 after acquiring an additional 262,874 shares during the period. Ensign Peak Advisors Inc raised its holdings in Outset Medical by 71.8% during the fourth quarter. Ensign Peak Advisors Inc now owns 560,169 shares of the company’s stock worth $2,078,000 after purchasing an additional 234,082 shares during the last quarter. Alyeska Investment Group L.P. raised its holdings in Outset Medical by 10.2% during the third quarter. Alyeska Investment Group L.P. now owns 1,614,582 shares of the company’s stock worth $22,798,000 after purchasing an additional 150,000 shares during the last quarter. Balyasny Asset Management L.P. purchased a new stake in Outset Medical during the second quarter worth $2,750,000. Finally, Bank of America Corp DE boosted its position in Outset Medical by 37,130.1% during the second quarter. Bank of America Corp DE now owns 135,890 shares of the company’s stock worth $2,610,000 after purchasing an additional 135,525 shares in the last quarter.

Insider Buying and Selling at Outset Medical

In related news, CFO Renee Gaeta sold 17,672 shares of the firm’s stock in a transaction that occurred on Wednesday, June 3rd. The shares were sold at an average price of $4.94, for a total value of $87,299.68. Following the sale, the chief financial officer directly owned 113,753 shares of the company’s stock, valued at approximately $561,939.82. This trade represents a 13.45% decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available at the SEC website. The sale was made to cover tax withholding obligations related to the vesting of equity awards. In the last 90 days, insiders have sold 25,337 shares of company stock worth $115,660. Corporate insiders own 2.50% of the company’s stock.

Outset Medical Stock Performance

Outset Medical stock opened at $4.36 on Friday. The stock has a fifty day moving average price of $4.45 and a 200 day moving average price of $4.26. Outset Medical, Inc. has a 52 week low of $3.00 and a 52 week high of $19.60. The firm has a market capitalization of $80.83 million, a P/E ratio of -1.05 and a beta of 1.95. The company has a current ratio of 6.29, a quick ratio of 4.97 and a debt-to-equity ratio of 0.87.

Outset Medical (NASDAQ:OM) last issued its quarterly earnings results on Thursday, May 7th. The company reported ($0.83) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.79) by ($0.04). The business had revenue of $27.86 million during the quarter, compared to analyst estimates of $28.90 million. Outset Medical had a negative return on equity of 56.13% and a negative net margin of 63.65%. Equities research analysts anticipate that Outset Medical, Inc. will post -3.82 earnings per share for the current year.

Analyst Ratings Changes

A number of research analysts have recently weighed in on the company. Weiss Ratings restated a “sell (e+)” rating on shares of Outset Medical in a research report on Wednesday, June 24th. Wall Street Zen cut shares of Outset Medical from a “hold” rating to a “sell” rating in a research note on Saturday, April 11th. Finally, TD Cowen reissued a “buy” rating on shares of Outset Medical in a research note on Friday, May 8th. Three investment analysts have rated the stock with a Buy rating, one has given a Hold rating and one has assigned a Sell rating to the stock. According to data from MarketBeat, Outset Medical presently has a consensus rating of “Hold” and an average target price of $10.00.

About Outset Medical

Outset Medical is a medical technology company specializing in innovations for renal care. The company’s flagship offering, the Tablo Hemodialysis System, is designed to streamline and simplify dialysis treatment across acute and outpatient settings. By integrating water purification, dialysate production, and treatment monitoring into a single device, Tablo aims to reduce the complexity and logistical burden traditionally associated with hemodialysis therapy.

Tablo’s modular design allows for rapid setup and flexible deployment in hospitals, clinics, long‐term care facilities and emergency response scenarios.